Success Metrics

Completion Rate
0%(0/2)
Active Trials
2(33%)
Terminated
2(33%)

Phase Distribution

Ph early_phase_1
1
17%
Ph phase_1
4
67%
Ph not_applicable
1
17%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
4(66.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Terminated(3)
Other(1)

Detailed Status

Terminated2
Active, not recruiting1
Recruiting1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (16.7%)
Phase 14 (66.7%)
N/A1 (16.7%)

Trials by Status

active_not_recruiting117%
recruiting117%
unknown117%
terminated233%
withdrawn117%

Recent Activity

2 active trials
Showing 5 of 6
recruitingearly_phase_1

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

NCT04744116
active_not_recruitingnot_applicable

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

NCT06849921
terminatedphase_1

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03691376
terminatedphase_1

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

NCT03240861
withdrawnphase_1

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

NCT03506802
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04744116Early Phase 1

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Recruiting
NCT06849921Not Applicable

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

Active Not Recruiting
NCT03691376Phase 1

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated
NCT03240861Phase 1

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated
NCT03506802Phase 1

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Withdrawn
NCT02108132Phase 1

Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia

Unknown

All 6 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
6